Topical effects of atorvastatin on induced ocular hypertension in rabbits
Paper Details
Topical effects of atorvastatin on induced ocular hypertension in rabbits
Abstract
Glaucoma defined as a group of optic neuropathies characterized by elevated intraocular pressure which is the most important factor and progressive retinal ganglion cells degeneration. Atorvastatin has an intraocular pressure lowering effect by blocking the Rho Kinase signaling pathway by increase aqueous humor outflow by reversing structural and functional damage at the trabecular meshwork leading to vasodilation and decrease the episacral venous pressure. The present study was conducted to evaluate the intraocular lowering effect, anti-oxidant and anti-inflammatory effects of atorvastatin in ocular hypertensive in rabbits.Group of (40)adult male of New Zealand rabbits, were divided to 3 groups: isotonic buffer group (8 normotensive rabbits), this group was instilled with isotonic buffer solution in the right eye and distilled water in the left eye to show if there is any effect of the vehicle (isotonic solution) on the eye, latanoprost group(8 rabbits) were both eyes of this group have been induced for ocular hypertensive, the right eyes instilled with latanoprost (0.005%) drop once daily which considered as a positive control group, while the left eyes instilled with DW once daily which considered as a negative control group., atorvastatin group (24 rabbits), divided in to (3) subgroups 8 rabbits in each (0. 5%, 1%&2%) that instilled once daily. The results obtained in this study provide experimental evidences for the effectiveness of atorvastatin (0.5%, 1%, 2%) ophthalmic solutions on the reduction of mean IOP and have an antioxidant and anti-inflammatory effect in induced ocular hypertensive eyes in rabbits.
Achilles JP. 2007. Cholinocepter-Activation & Cholinesterase-Inhibiting drugs: Katzung B.G. Basic and Clinical Pharmacology. 10th ed. McGraw Hill. Boston, p 103.
Ahuja M. 2003. Ophthalmology Handbook. 1st ed. India Binding House. Delhi, p 145-163.
Allen LV, Popovich NG, Ansel HC. 2005. Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. 8th ed. Lippincott Williams and Wilkins. Philadelphia p 540-569.
Chang EE, Goldberg JL. 2012. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology 119(5), 979-86. http://dx.doi.org/10.1016/j.ophtha.2011.11.003
Daniel A, Yu X. 2008. Statistical Methods for Categorical Data Analysis, 2nd edition, London.
Ferreira SM, Lerner SF, Brunzini R, Evelson PA, Llesuy SF. 2004. Oxidative stress markers in aqueous humor of glaucoma patients. American Journal of Ophthalmology 137(1), 62-9.
Flecknell PA. 2009. Laboratory Animal Anesthesia. Third edition. London: Academic press, p 304.
Glaucoma research foundation. 2017. Types of glaucoma, https://www.glaucoma.org/glaucoma/types-of-glaucoma.php accessed .4.9 .2018
Goel M, Picciani RG, Lee RK, Bhattacharya SK. 2010. Aqueous Humor Dynamics: A Review. The Open Ophthalmology Journal 4, 52-59. http://dx.doi.org/10.2174/1874364101004010052.
Green CJ, Knight J, Precious S, Simpkin S. 1981. Ketamine alone and combined with diazepam or xylazine in laboratory animals: a 10 year experience. Laboratory Animals 15, 163-170.
Gupta N, Yucel YH. 2007. Should we treat the brain in glaucoma? Journal of Ophthalmology 42, 409–13.
Gupta SK, Kalaiselvan V, Agrawal SS, Srivastava S, Saxena R. 2011. Prevention of endotoxin-induced uveitis in rabbits by Triphala an Ayurvedic formulation. International Journal of Current Pharmaceutical Research 1(2), 20–23.
Hecht G. 2000. Ophthalmic preparations. ch. 89, 1563-1573.
Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. 2002. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Archives of Ophthalmology 120, 1268–1279.
Jampel H. 2001. Intraocular pressure. In: Gross R.L. Clinical Glaucoma Management. W.B. Saunders Company. Philadelphia, p 403-413.
Jay JL, Murdoch JR. 1993. The rate of visual field loss in untreated primary open angle glaucoma. British Journal of Ophthalmology 77, 176-182.
Kaushik S, Pandav SS, Ram J. 2003. Neuroprotection in glaucoma. Journal of Postgraduate in Medicine 49, 90–5.
Kierstan B. 2017. American Academy of Ophthalmology; Glaucoma treatment. https://www.aao.org/eye-health/diseases/glaucoma-treatment
Liao JK, Laufs U. 2005. Pleiotropic effects of statins. Annual Review of Pharmacology and Toxicology 45, 89-118.
Luksch A. 2000. Effects of Systemic NO Synthase Inhibition on Choroidal and Optic Nerve Head Blood Flow in Healthy Subjects. Investigative Ophthalmology & Visual Science 41, 3080-3084.
Macdonald M. 2000. The examination of the eye. In: Munro J. and Edwards C. Macleod’s Clinical Examination. 10th .ed. Churchill Livingstone. Edinburgh, p. 257-271.
Mason JC. 2003. Statins and their role in vascular protection. Clinical Sciences 105, 251-66.
McKinnon SJ, Goldberg LD, Peeples P, Walt JG, Bramley TJ. 2008. Current management of glaucoma and the need for complete therapy. The American Journal of Managed Care 14, S20–27.
Melena J, Santafé J, Segarra J. 1998. The effect of topical diltiazem on the intraocular pressure in betamethasone-induced ocular hypertensive rabbits. The Journal of Pharmacology and Expiremental Therapeutics 284(1), 278-82.
Mohammad K, Haitham M, Waleed KA. 2018. Effect of Telmisartan on Intra-Ocular Pressure in induced Open Angle Glaucoma in Rabbits. International Journal of Science and Research 6(10), 1656-1657.
Moses RA. 1997. Intraocular pressure. In: Moses R.A. and Hart W.M. Alder’s Physiology of the eye Clinical Application. 9th ed. Mosby Company. St. Louis, p 223-245.
Ohnesorge N, Viemann D, Schmidt N, Czymai T, Spiering D, Schmolke M. 2010. Erk5 activation elicits a vasoprotective endothelial phenotype via induction of Kruppel-like factor 4 (KLF4). The Journal of Biological Chemistry 285, 26199–210.
Patelska B, Greenfield DS, Liebmann JM, Wand M, Kushnick H, Ritch R. 1997. Latanoprost for Uncontrolled Glaucoma in a Compassionate Case Protocol. American Journal of Ophthalmology 124(3), 279–286.
Perry MP, McGavin JK, Culy CR, Ibbotson T. 2003. Latanoprost. An update of its use in glaucoma and ocular hypertension. Drug Aging 28, 183-98.
Rao PV. 2001. Modulation of Aqueous Humor Outflow Facility by the Rho Kinase-Specific Inhibitor Y27632. Investigative Ophthalmology & Visual Science 42, 1029-1037.
Urcola JH, Hernandez M, Vecino E. 2002. A study of experimental hydroxypropyl methylcellulose glaucoma and other experimental glaucoma in rabbits. Experimental Eye Research 38, 172-175.
Weinreb RN, Aung T, Medeiros FA. 2014. The Pathophysiology and Treatment of Glaucoma A Review. Journal of the American Medical Association 311(18), 1901-1911. http://dx.doi.org/10.1001/jama.2014.3192.
Weinreb RN, Levin LA. 1999. Is neuroprotection a viable therapy for glaucoma? Archives Ophthalmology 117, 1540–4.
WHO Word health organization. 2017. Vision impairment and blindness. Available at; http://www.who.int/mediacentre/factsheets/fs282/en/.
Ali H. Jasim, Haitham M. Kadhim, Ahmed Majeed Rasheed, 2019. Topical effects of atorvastatin on induced ocular hypertension in rabbits. Int. J. Biosci., 14(2), 272-282.
Copyright © 2019 by the Authors. This article is an open access article and distributed under the terms and conditions of the Creative Commons Attribution 4.0 (CC BY 4.0) license.